Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Work In Process (2017 - 2024)

China Pharma Holdings (CPHI) has disclosed Work In Process for 8 consecutive years, with $334430.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Work In Process fell 50.59% year-over-year to $334430.0, compared with a TTM value of $334430.0 through Sep 2024, down 50.59%, and an annual FY2023 reading of $413597.0, down 25.77% over the prior year.
  • Work In Process was $334430.0 for Q3 2024 at China Pharma Holdings, up from $87308.0 in the prior quarter.
  • Across five years, Work In Process topped out at $676885.0 in Q3 2023 and bottomed at $87308.0 in Q2 2024.
  • Average Work In Process over 5 years is $431457.2, with a median of $423493.0 recorded in 2020.
  • The sharpest move saw Work In Process soared 110.99% in 2020, then crashed 76.07% in 2024.
  • Year by year, Work In Process stood at $662999.0 in 2020, then decreased by 15.97% to $557146.0 in 2021, then changed by 0.0% to $557146.0 in 2022, then dropped by 25.77% to $413597.0 in 2023, then fell by 19.14% to $334430.0 in 2024.
  • Business Quant data shows Work In Process for CPHI at $334430.0 in Q3 2024, $87308.0 in Q2 2024, and $242726.0 in Q1 2024.